RHÖN-KLINIKUM AG  / Key word(s): Mergers & Acquisitions/Forecast

09.02.2012 20:25

Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.



Ad hoc notice according to section 15 German Securities Trading Act (WpHG)

RHÖN-KLINIKUM AG

  - City of Wiesbaden in favour of RHÖN-KLINIKUM AG acquiring equity
    interest in Dr.-Horst-Schmidt-Kliniken.

  - Outlook for 2012 is refined

Bad Neustadt a.d. Saale, 9 February 2012

By a large majority, Wiesbaden City Council today gave its approval for the
sale of a 49 per cent equity interest in Dr.-Horst-Schmidt-Kliniken (HSK)
to RHÖN-KLINIKUM AG. As part of this interest, the private hospital
operator is to assume entrepreneurial management of the biggest hospital in
Wiesbaden, Federal State Capital of Hesse, and to also initiate the
refurbishment and modernisation of its building infrastructure.

'We are pleased with the tremendous trust the city councillors and
Wiesbaden City Council have placed in us. With our restructuring expertise,
we will return HSK to profit and make it a viable facility', said Wolfgang
Pföhler, chairman of the Board of Management of RHÖN-KLINIKUM AG.

Each year, Dr.-Horst-Schmidt-Kliniken treats a total of roughly 43
thousand patients in 1,027 beds and generates revenues of over EUR 200
million. As a maximum-care hospital, HSK employs roughly 3,100 employees at
three sites.

Execution of the transaction requires formal approval by the social,
municipal supervisory and cartel authorities, and is moreover subject to
the reservation of a possible referendum opposing the share's sale. The two
parties agreed to maintain secrecy regarding the purchase price.

As part of this recent participating interest, the Group refines its
forecast for the current financial year to also include a first-time
consolidation of HSK slated for the second quarter of 2012.
 
For 2012 including HSK, RHÖN-KLINIKUM AG expects revenues of EUR 2.85
billion which may fluctuate within a range of plus or minus 2.5 per cent.
This revenue target is accompanied by a forecast for EBITDA of EUR 350
million and for net consolidated profit of EUR 145 million - in each case
influenced by a negative earnings contribution from the HSK consolidation
and subject to a fluctuation range of plus or minus five per cent. In the
event of the first-time consolidation of HSK being delayed, adjustments to
individual revenue and earnings figures may become necessary during the
year.

The Board of Management


Contact:

Dr. Kai G. Klinger
Head of Investor Relations

RHÖN-KLINIKUM AG
Corporate Division of
Finance, Investor Relations, Controlling
Schlossplatz 1
D-97616 Bad Neustadt a. d. Saale

Tel.:      +49 (0)9771-65.13 18
Fax:       +49 (0)9771-99.17 36
Mobile:    +49 (0)151-12 58 27 07
E-mail:    kai.klinger@rhoen-klinikum-ag.com
web:       www.rhoen-klinikum-ag.com

Chairman of the Supervisory Board: Eugen Münch
Board of Management: Wolfgang Pföhler (chairman), Volker Feldkamp, Dr. Erik
Hamann, Martin Menger, Dr. Irmgard Stippler
Registered office of Company: Bad Neustadt a. d. Saale
Register Court of Schweinfurt HRB 1670


09.02.2012 DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de


 
Language:     English
Company:      RHÖN-KLINIKUM AG
              Schlossplatz 1
              97616 Bad Neustadt a.d.Saale
              Germany
Phone:        +49 (0)9771 - 65-0
Fax:          +49 (0)9771 - 97 467
E-mail:       rka@rhoen-klinikum-ag.com
Internet:     www.rhoen-klinikum-ag.com
ISIN:         DE0007042301
WKN:          704230
Indices:      MDAX
Listed:       Regulierter Markt in Frankfurt (Prime Standard), München;
              Freiverkehr in Berlin, Düsseldorf, Hamburg, Stuttgart
 
End of Announcement                             DGAP News-Service